U.S. markets open in 9 hours 28 minutes

Novo Nordisk A/S (NONOF)

OTC Markets OTCPK - OTC Markets OTCPK Precio retrasado. Moneda en USD.
Añadir a la lista de seguimiento
144.950.00 (0.00%)
Al cierre: 01:51PM EDT

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo66,015

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Lars Fruergaard JorgensenPresident, CEO & Member of Management Board4.68MN/D1966
Mr. Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board1.86MN/D1971
Mr. Henrik Ehlers WulffExecutive VP of Product Supply, Quality & IT and Member of the Management Board1.87MN/D1970
Ms. Camilla SylvestExecutive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board1.83MN/D1972
Dr. Martin Holst LangeExecutive VP of Development & Member of the Management Board1.77MN/D1970
Dr. Marcus Schindler Ph.D.EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board1.77MN/D1966
Mr. Maziar Mike DoustdarExecutive VP of International Operations & Member of the Management BoardN/DN/D1970
Mr. Douglas J. LangaExecutive VP of North America Operations & Member of Management BoardN/DN/D1966
Mr. Ludovic HelfgottExecutive VP, Head of Rare Disease & Member of Management BoardN/DN/D1974
Ms. Tania SabroeExecutive VP of Global People & Organisation and Member of Management BoardN/DN/D1977
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Gestión corporativa

La calificación ISS Governance QuickScore de Novo Nordisk A/S a partir del 1 de junio de 2024 es 1. Las puntuaciones principales son Auditoría: 3; Junta: 3; Derechos del accionista: 9; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.